
Gordon K. Norman, MD, MBA. Author reply by Soeren Mattke, MD, DSc
Advertisement
Articles by Gordon K. Norman, MD, MBA. Author reply by Soeren Mattke, MD, DSc

Advertisement
Latest Updated Articles
All Things Considered, the Answer Is a Resounding YesPublished: January 15th 2008 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Inebilizumab for Generalized Myasthenia Gravis
2
Clascoterone 5% Delivers Strong Phase 3 Results for Androgenetic Alopecia
3
Cardiotoxicity Remains a Concern as Breast Cancer Survival Rates Improve: Eric H. Yang, MD
4
5 Key Oncology FDA Approvals From November
5



